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A detailed understanding of the interactions between small-molecule ligands
and their proposed binding targets is of the utmost importance for modern
drug-development programs. Cellular retinoic acid-binding proteins I and II
(CRABPI and CRABPII) facilitate a number of vital retinoid signalling
pathways in mammalian cells and offer a gateway to manipulation of signalling
that could potentially reduce phenotypes in serious diseases, including cancer
and neurodegeneration. Although structurally very similar, the two proteins
possess distinctly different biological functions, with their signalling influence
being exerted through both genomic and nongenomic pathways. In this article,
crystal structures are presented of the L29C mutant of Homo sapiens CRABPI
in complex with naturally occurring fatty acids (1.64 Å resolution) and with the
synthetic retinoid DC645 (2.41 Å resolution), and of CRABPII in complex with
the ligands DC479 (1.80 Å resolution) and DC645 (1.71 Å resolution). DC645
and DC479 are two potential drug compounds identified in a recent synthetic
retinoid development program. In particular, DC645 has recently been shown to
have disease-modifying capabilities in neurodegenerative disease models by
activating both genomic and nongenomic signalling pathways. These co-crystal
structures demonstrate a canonical binding behaviour akin to that exhibited
with all-trans-retinoic acid and help to explain how the compounds are able to
exert an influence on part of the retinoid signalling cascade.
1. Introduction
The cellular retinoic acid-binding proteins CRABPI and
CRABPII act as gatekeepers and facilitators for the passage
of all-trans-retinoic acid (and related derivatives) through the
cytoplasm to access retinoic acid receptors (RARs) in the
nucleus. This journey is of eminent importance, as retinoid
signalling has a huge impact on the growth and development
of mammalian organisms throughout their lifetimes, with a
particular focus on embryonic development. Beyond this, the
general retinoid signalling system and vitamin A-utilization
pathways are relied upon for vision and skin health, and have
been implicated in the treatment of various cancers and
neurodegenerative diseases (Moon et al., 1979; Cowan et al.,
2017; Sahin et al., 2005; Katz et al., 1999; Khatib et al., 2019,
2020).
CRABPI shares high sequence identity (77%) with
CRABPII but, unlike its sister protein, does not contain the
appropriate residues to form a nuclear localization sequence
(NLS). As a result, it localizes entirely into the cytoplasm and
carries out the role of buffering retinoid concentrations within
the cell, aiding in the degradation of retinoids via cytochrome
P450s (Ross & Zolfaghari, 2011). Additionally, CRABPI can
ISSN 2059-7983
modulate several putative nongenomic pathways: the ERK1/2
kinase pathway is dose-dependently modified by the complex
of CRABPI with all-trans-retinoic acid (ATRA) via sequential
interactions with Raf, MEK and ERK kinases (Park et al.,
2019; Persaud et al., 2013), and in mice the calmodulin-
dependent protein kinase pathway is modified by reduced
autophosphorylation of CaMKII in the presence of CRABPI
(Park et al., 2018).
In contrast, CRABPII acts as flagship for ATRA transport
in mammalian cells and is capable of nuclear localization
owing to a ‘noncanonical nuclear localization sequence’
composed of three residues, Lys20, Arg29 and Lys30, which
are located spatially together across the helical cap when the
protein is ligand-bound but are separated by several residues
in the primary sequence (Sessler & Noy, 2005). This allows
CRABPII to ferry retinoic acid from the cytoplasm into the
nucleus, where it is further transferred to the RAR/RXR
nuclear receptors (Budhu et al., 2001). The retinoic acid-
binding ability of both CRABPI and CRABPII is centred on a
hydrophobic pocket created by an orthogonal -sheet fold and
capped with a pair of antiparallel -helices formed from
residues 15–35 partway into the sequence (Kleywegt et al.,
1994). The pocket contains, at its most buried end, a trio of
residues (Arg112, Arg132 and Tyr134 in CRABPI; Arg112,
Arg133 and Tyr135 in CRABPII) that are responsible for
binding to the carboxylic acid moiety of ATRA, usually in
concert with a water molecule that is conserved in all struc-
tures with similarly binding ligands. The rest of the pocket is
lined with hydrophobic residues that create a suitable envir-
onment for the unsaturated, fatty-acid-like portion of ATRA
and, when unoccupied, contains a network of water molecules
that support the fold (Vaezeslami et al., 2008). The hydro-
phobic contribution to the binding energy is considerable, as
even when other elements of the binding mode are disturbed
by mutation, general binding efficiency is maintained (Vasi-
leiou et al., 2009). The structure of CRABPII has previously
been determined in both ligand-occupied (by ATRA and
synthetic retinoids; Chaudhuri et al., 1999) and non-occupied
states using both mutants (Chen et al., 1998) and the wild-type
protein (Vaezeslami et al., 2006). This cache of structural
knowledge has allowed the determination of the nuclear
localization sequence, as discussed previously (Sessler & Noy,
2005), as well as the development of a protein-engineering
scheme to create a pH biosensor (Berbasova et al., 2013).
ATRA has been in use therapeutically since the 1980s
(Kligman et al., 1984), but stability issues (UV photosensitivity
and a proclivity for isomerization in solution) and a wide
variety of off-target side effects (Tallman, 2002) have limited
its impact for the treatment of complex neurological and
oncological disorders. Conversely, the development of stable,
activity-modifying retinoid derivatives (Chisholm et al., 2016,
2019; Chisholm & Whiting, 2020; Haffez et al., 2017) is now
providing a greater understanding of how retinoid signalling
pathways are controlled and how intervention could poten-
tially improve the outlook for patients suffering diseases that
could be challenged through retinoid intervention. Small,
retinoid-like molecules are becoming increasingly important
not only as drug candidates but also as part of the drug-
screening process, with fluorescence-based assays and other
high-throughput methodologies using their interactions with
CRABPII (and other proteins) to discover and characterize
the binding of small molecules from vast libraries of potential
compounds (Tomlinson et al., 2018; Yamada et al., 2019;
Tomlinson & Whiting, 2020). Understanding the structural
impact of these molecules and how they may influence
retinoid-related signalling outcomes through CRABPII–RAR
interaction, as well as moderating nongenomic signalling
effects through CRABPI, is a key step in the development of
new potentially life-altering treatments.
2. Methods
2.1. Expression of CRABPII
GST-tagged CRAPBII protein was expressed in Escherichia
coli BL21 (DE3) competent cells (New England Biolabs)
transformed with a pGEX4T1-hCRABPII vector (canonical
sequence UniProt P29373) optimized for expression in E. coli.
Expression was started from 25 ml starter cultures (25 g l1
LB broth, 100 mg ml1 ampicillin), which were transferred to
1 l cultures after overnight incubation at 37C. Expression was
induced after 4 h of shaking (37C, 150 rev min1) with
isopropyl -d-1-thiogalactopyranoside (IPTG; final concen-
tration of 1 mM in the culture) before shaking overnight for
20 h. The resulting cultures were pelleted using an Avanti Hi-
Speed centrifuge (JLA 8.1000, 4000 rev min1, 25 min, 4C)
before removal of the supernatant and freezing at 80 C.
2.2. Purification of CRABPII
Defrosted cell pellets were resuspended in 15 ml cold lysis
buffer [10 mM DTT, 100 mM MgCl2 in phosphate-buffered
saline (PBS) pH 7.5] and lysed with the addition of
0.5 mg ml1 lysozyme for 30 min. The resulting suspension
was sonicated on ice (2 min, 40% power) and centrifuged
(20 000 rev min1, 50 min, 4C). The supernatant was loaded
onto a GST affinity column (1 ml, GE Healthcare) and washed
with 30 ml PBS pH 7.5. The column was then loaded with 1 ml
thrombin in PBS (GE Healthcare) and kept at room
temperature for 16 h to cleave the GST tag. The cleaved
protein was eluted in 3  1 ml fractions using PBS pH 7.5 and
the bound GST tag was eluted using 5 ml reduced glutathione
(10 mM in PBS). The resulting protein fractions were analysed
by SDS–PAGE and ESI mass spectrometry, and the concen-
tration was estimated from the absorbance at 280 nm using a
Thermo Scientific Nanodrop A280.
2.3. Expression of CRABPI-L29C
The L29C mutant of CRABPI (CRABPI-L29C) was
heterologously expressed in E. coli BL21 (DE3) competent
cells (New England Biolabs) transformed with a pET28a-
hCRABPIL29C vector (canonical sequence UniProt P29762
with an L29C modification). 25 ml starter cultures (25 g l1 LB
broth, 50 mg l1 kanamycin) were incubated with shaking
overnight (150 rev min1, 37C) and then transferred into 1 l
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expression flasks (LB/kanamycin) and grown with shaking at
37C and 150 rev min1. Induction with 1 ml 1 M IPTG (final
concentration of 1 mM in the culture) was carried out at an
OD600 of 0.6 before shaking overnight (20 h) at 25
C. The
resulting cultures were pelleted using an Avanti Hi-Speed
centrifuge (JLA 8.1000, 4000 rev min1, 25 min, 4C) before
the supernatant was removed and the bacterial pellet frozen at
80C.
2.4. Purification of CRABPI-L29C
CRABPI-L29C pellets were resuspended in 15 ml loading
buffer (10 mM imidazole, 500 mM NaCl, 20 mM Tris–HCl
pH 8). The resulting suspension was sonicated on ice (40%
power, 2 min) and centrifuged (Avanti Hi-Speed JA25.50,
20 000 rev min1, 50 min, 4C). The supernatant was loaded
onto a HisTrap HP column (1 ml, GE Healthcare) and washed
using 30 ml loading buffer. Elution was carried out in a smooth
gradient with elution buffer (500 mM imidazole, 500 mM
NaCl, 20 mM Tris–HCl pH 8) on an ÄKTA pure FPLC. The
resulting protein fractions were analysed by SDS–PAGE and
the concentration was estimated using a Thermo Scientific
Nanodrop A280. CRABPI-L29C was incubated overnight
with thrombin (80 U) to cleave the His tag and dialysed into
fresh buffer without imidazole (500 mM NaCl, 20 mM Tris–
HCl pH 8). The results of this digest were loaded onto a
HisTrap HP column (1 ml, GE Healthcare) and the cleaved
protein was eluted immediately using 3 ml loading buffer into
3 1 ml fractions. The bound tag was then eluted with elution
buffer and the column was washed to remove any other
contaminants. The resulting protein and tag fractions were
analysed by SDS–PAGE and Nanodrop A280 before use in
assays and crystallization experiments.
2.5. Analytical size-exclusion chromatography of
CRABPI-L29C
CRABPI-L29C was analysed for dimerization following
the purification stages. 1 ml protein solution (6.8 mg ml1,
500 mM NaCl, 20 mM Tris–HCl pH 8) was loaded onto a
HiLoad 16/600 Superdex 75 pg column equilibrated in the
same buffer using an ÄKTA pure FPLC. Elution was carried
out at 1 ml min1 over 3 h (1.5 column volumes in total) and
fractionated into 2 ml fractions. The fractions making up the
two key peaks were analysed by SDS–PAGE to demonstrate
purity and protein mass, and the fractionation volumes were
compared with a standard curve prepared previously. One
peak consisted of monomeric CRABPI-L29C and the other
corresponded by mass to a dimeric form of the protein. The
resulting fractions were spun down and their concentrations
were calculated to determine the fraction of dimerization.
2.6. Crystallization
Diffraction-grade crystals were grown by screening condi-
tions from commercially available crystallization kits. Purified
proteins were combined with the co-crystallized retinoid
(dissolved in ethanol) in a 1:1 equimolar fashion, ensuring that
the overall ethanol content remained low. Screening was
carried out using a Mosquito Xtal3 robot (SPT Labtech) in
sitting-drop experiments (100 + 100 and 200 + 100 nl protein +
reservoir drop sizes) and was followed up by optimization in
sitting-drop experiments (400 ml reservoir solution) with
varying drop sizes (1 + 1 and 2 + 1 ml protein + reservoir
solution). The resulting crystals were inspected with a micro-
scope and were mounted for diffraction using standard
UniPuck-style pins before flash-cooling in liquid N2 (Teng,
1990).
CRABPI-L29C in complex with myristic acid (CRABPI-
L29C–MYR) was crystallized using 0.1 M sodium citrate pH
5.5, 30% PEG 6000. CRABPI-L29C–DC645 was crystallized
using 0.1 M sodium acetate pH 5.0, 25% PEG 6000 based on
the optimization of a condition from PACT premier (Newman
et al., 2005) determined by robotic screening.
CRABPII–DC479 was crystallized using 0.1 M Tris–HCl pH
8.0, 0.2 M sodium sulfate, 25% PEG 4000. CRABPII–DC645
was crystallized using 0.1 M sodium citrate pH 5.4, 0.2 M
ammonium acetate, 30% PEG 3350.
2.7. Diffraction experiments
Diffraction experiments were carried out at Diamond Light
Source (DLS) as part of the BAG program. Beamline I24 was
used to collect data for CRABPII–DC645, beamline I03 was
used for data collection for CRABPI-L29C–MYR and
CRABPII–DC479, and beamline I04 was used for data
collection for CRABPI-L29C–DC645. Further details are
summarized in Table 1.
2.8. Data processing
Data processing was carried out using the CCP4 suite of
programs as well as XDS (Kabsch, 2010) as part of the
autoprocessing performed at DLS. Scaling was carried out
with AIMLESS/POINTLESS (Evans & Murshudov, 2013),
phasing was performed via molecular replacement with Phaser
(McCoy et al., 2007) and manual modifications to the model
were made with Coot (Emsley et al., 2010). REFMAC5 was
used for refinement (Murshudov et al., 1997, 1999, 2011; Vagin
et al., 2004; Winn et al., 2003; Nicholls et al., 2012).
In the case of CRABPI-L29C, disulfide-bond restraints
were added using SSBOND comments to suitably refine the
interaction of Cys29 of chain A with Cys29 of chain B of the
symmetry mate using REFMAC5.
In the CRABPI-L29C structures and that of CRABPII–
DC479, local NCS restraints generated by REFMAC5 were
used to improve the refinement of the structures containing a
dimer or two-monomer unit (Murshudov et al., 2011; Usón et
al., 1999). Refinement statistics are given in Table 2.
Alignments and figure production were carried out using
CCP4mg (McNicholas et al., 2011).
2.9. Binding assays of CRABPI-L29C and CRABPII
Solutions of DC271 (300 nM in <1% ethanol), CRABPII
(300 nM in PBS) and CRABPI-L29C (300 nM in 20 mM
HEPES, 300 mM NaCl pH 7.5) and a dilution series of DC645
(9.6 mM to 4.68 nM in <1% ethanol) were prepared. 50 ml
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volumes were combined in a Corning nonbinding-surface
black fluorescence plate using H2O in place of retinoids and
PBS/HEPES buffer in place of CRABPII/CRABPI-L29C
when necessary for controls. The plate was spun for 2 min
(1500 rev min1) to ensure incorporation and the fluorescence
was read with excitation at 335 nm and emission at 440 nm
using a Synergy H4 plate reader. The total volume per well
was 150 ml and the final concentration of protein and DC271
was 100 nM. The assay was adapted from Tomlinson et al.
(2018), with additional control for intrinsic fluorescence of
DC645.
3. Results
3.1. Crystal structure of CRABPI-L29C–MYR
CRABPI was first crystallized and its crystal structure
reported in 1994 (Kleywegt et al., 1994) using the proteins
from Mus musculus and Bos taurus, and current PDB
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Table 2
Structure solution and refinement.
Values in parentheses are for the outer shell.
CRABPI-L29C–MYR CRABPI-L29C–DC645 CRABPII–DC479 CRABPII–DC645
Resolution range (Å) 36.05–1.64 110.46–2.41 66.99–1.80 45.36–1.71
Completeness (%) 99.9 (100.0) 99.9 (99.3) 99.6 (99.1) 100.0 (100.0)
No. of reflections, working set 43108 19078 23016 17753
No. of reflections, test set 2049 848 1125 889
Final Rcryst 0.19 0.20 0.19 0.18
Final Rfree 0.22 0.25 0.25 0.20
No. of non-H atoms
Protein 2212 2158 2184 1091
Ligand 37 25 52 25
Water 154 39 158 89
Total 2403 2222 2394 1205
R.m.s. deviations
Bonds (Å) 0.0121 0.0088 0.0083 0.0120
Angles () 1.699 1.559 1.547 1.745
Average B factors (Å2)
Protein 37.11 57.51 30.19 39.21
Ligand 51.40 49.98 27.41 32.24
Water 45.79 44.85 37.43 44.93
Ramachandran plot
Most favoured (%) 97.03 95.88 95.94 97.78
Allowed (%) 2.23 3.00 3.32 1.48
High energy (%) 0.74 1.12 0.74 0.74
Table 1
Data collection and processing.
Values in parentheses are for the outer shell.
CRABPI-L29C–MYR CRABPI-L29C–DC645 CRABPII–DC479 CRABPII–DC645
PDB code 7a9y 7a9z 7aa0 7aa1
Diffraction source I03, DLS I04, DLS I03, DLS I24, DLS
Wavelength (Å) 0.9763 0.9763 0.9763 0.9763
Temperature (K) 100 100 100 100
Detector PILATUS 6M PILATUS 6M PILATUS 6M PILATUS 6M
Crystal-to-detector distance (mm) 213.39 385.58 321.83 186.39
Rotation range per image () 0.1 0.1 0.1 0.1
Total rotation range () 200 360 200 180
Exposure time per image (s) 0.05 0.05 0.05 0.1
Space group I222 P3121 P21 P213
a, b, c (Å) 36.89, 109.98, 170.34 127.54, 127.54, 52.16 39.56, 49.92, 67.37 78.56, 78.56, 78.56
, ,  () 90.0, 90.0, 90.0 90.00, 90.00, 120.00, 90.00, 96.04, 90.00 90.0, 90.0, 90.0
Mosaicity () 0.00 0.00 0.70 0.00
Resolution range (Å) 36.05–1.64 110.46–2.41 49.92–1.82 45.36–1.71
Total No. of reflections 81769 366266 80669 326013
No. of unique reflections 43112 19102 23023 17775
Completeness (%) 99.9 (100) 99.9 (99.3) 97.6 (96.8) 100.0 (100.0)
Multiplicity 1.9 (1.9) 19.2 (16.8) 3.5 (3.7) 18.3 (18.3)
CC1/2 0.998 (0.480) 0.994 (0.398) 0.996 (0.486) 0.999 (0.548)
hI/(I)i 9.8 (1.1)† 7.1 (0.5)† 10.4 (1.6)† 18.8 (1.2)†
Rp.i.m. 0.029 (0.559) 0.088 (1.624) 0.059 (0.504) 0.019 (0.554)
Overall B factor from Wilson plot (Å2) 26.42 47.34 26.78 31.81
† The resolution cutoff was automatically selected based on CC1/2 rather than outer shell I/(I).
depositions extend to 2.7 Å resolution (PDB entry 1cbi;
Thompson et al., 1995). As part of crystal-screening efforts, we
identified that an L29C mutation in Homo sapiens CRABPI
allowed vastly improved crystallization and diffraction to
atomic resolution, which was subsequently determined to be
due to partial dimerization at the mutated surface residue.
This mutation is found on the outer edge of the cap helices and
as such does not affect the make-up of the hydrophobic
binding site.
As can be seen in Fig. 1, the structure (determined at a
resolution of 1.64 Å) retains an overall architecture identical
to that of wild-type CRABPI (r.m.s.d. of 0.69 Å to PDB entry
1cbr on C atoms) in a stable crystal form consisting of two
molecules that share noncrystallographic symmetry (r.m.s.d.
of 0.53 Å between chains A and B on C atoms) in the
asymmetric unit, each separately dimerized with a symmetry
mate. This dimerization was characterized by size-exclusion
chromatography (Superdex 75 16/600) and shown to affect
approximately one third of the purified protein, and is likely to
exist in equilibrium with the monomeric state. This was
corroborated by the presence of a dual conformation for
residue Cys29 in the second monomer that can be seen in the
electron density, only one version of which corresponds to a
disulfide bond of 2.1 Å. The crystal structure resulting from
molecular replacement contained unknown density in the
ligand-binding sites of both independent monomers that was
not suitable for fitting either ATRA or the synthetic ligands
used for co-crystallization. It was determined that this density
was most likely to represent fatty-acid byproducts from
expression that were incorporated into the binding site based
on their hydrophobic structure and carboxylic acid head
group, and it was therefore fitted as the 14-carbon myristic
acid (MYR) and the 13-carbon tridecanoic acid (TDA) in the
two monomers. CRABPI shares high sequence similarity with
other members of the fatty acid-binding protein family and so
the incorporation of MYR/TDA molecules is a logical step for
a protein produced recombinantly in E. coli in the absence of
its natural ligand. Similarly, it has been shown that RXRs and
other retinoid-binding proteins treat fatty acids (including
myristic acid) as ligands, and so it is possible that nongenomic
pathways are similarly influenced (Goldstein et al., 2003; de
Urquiza et al., 2000).
3.2. Crystal structure of CRABPI-L29C–DC645
After the determination of the initial structure, further
crystallization screening was carried out using an equimolar
mixture of protein and DC645, with the aim of proper inclu-
sion of the synthetic ligand, resulting in the structure shown in
Fig. 2. Also based on CRABPI-L29C, this structure was solved
at 2.41 Å resolution and contained a similar dimer, with one
unoccupied binding site and one site incorporating the DC645
ligand; the r.m.s.d. between the two sites, based on C atoms, is
0.66 Å. As in the MYR-containing structure, the asymmetric
unit contains a pair of molecules related by noncrystallo-
graphic symmetry; whilst one site is occupied by ligand, it is
notable that the empty binding site is truly empty, i.e. there is
no electron density evident that would suggest the incor-
poration of any alternate ligand. As the two monomers
otherwise adopt the same overall structure, there is no
immediately apparent reason for this difference. Similarly to
CRABPI-L29–MYR, CRABPI-L29C–DC645 dimerization
can be seen to occur across the noncrystallographic symmetry
boundary, with Cys29 in both the A and B chains structured
correctly to form the disulfide bridge, with no evidence that
any other conformation might be occurring. It can be seen that
the ligand occupies the binding site in a similar mode to the
natural ligand ATRA, with the carboxylic acid group buried
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Figure 1
(a) CRABPI-L29C with the binding triad (Arg112-Arg132-Tyr134) (ribbon representation, pale blue; O atoms, red; N atoms, blue) and a conserved
water molecule hydrogen-bonded to the associated ligand modelled as the 14-carbon myristic acid (stick representation, grey; O atoms, red; N atoms,
blue). The protein forms a dimer with noncrystallographic symmetry which, for clarity, has been omitted. Chain A is displayed, with an r.m.s.d. on C
atoms to chain B of 0.53 Å. (b) Ligand density of MYR in chain A in the ligand-binding site of CRABPI-L29C (2Fo Fc map including the ligand in the
calculation, at contour  = 1).
deep in the hydrophobic binding site adjacent to the binding
triad. The lack of structural rearrangement in the protein after
binding points to a more nuanced method for the involvement
of CRABPI in nongenomic signalling and retinoid buffering,
and is discussed in further detail below.
3.3. Crystal structure of CRABPII–DC479
Wild-type CRABPII expressed recombinantly in E. coli
proved to be reliable for crystallization in a repeatable manner
and accepted ligands for co-crystallization using an equimolar
combining step prior to setting up crystallization drops.
Seeking to identify ligands with unconventional binding-site
interactions with CRABPII, DC479 was chosen from a
number of small-molecule retinoids designed to substantially
improve upon the intrinsic fluorescence of the retinoid family
and particularly for use in high-throughput binding assays
(Chisholm et al., 2019; Chisholm & Whiting, 2020). Of parti-
cular interest was the extended carbon chain to which the
carboxylic acid group was appended, improving the flexibility
around the head group, to determine how ligand flexibility
would affect optimum binding into the triad site. The
compound binds to CRABPII with an affinity in the 50 nM
range, similar to those of other ‘strongly binding’ synthetic
derivatives, and thus was an ideal choice to explore ligand-
conformation space in terms of interactions with the protein
(Chisholm et al., 2019). Additionally, DC479 has been shown
to cause the activation of nongenomic pathways whilst having
no effect on genomic signalling; a result indicated by a lack of
neurite outgrowth in tests with in vitro models (Khatib et al.,
2020). Indeed, its interactions with CRABPII may indicate
why this is the case if the effect is caused by carrier-protein
interactions rather than RAR binding (or a lack thereof) in
the nucleus.
The structure presented here (1.80 Å resolution; Fig. 3)
agrees closely with previously determined CRABPII struc-
tures, including PDB entry 5ogb (C r.m.s.d. of 0.61 Å;
Chisholm et al., 2019), which was used for molecular
replacement. DC479 occupies the binding site fully, with its
carboxylic acid head buried adjacent to the canonical binding
triad and conserved water molecule. Correct incorporation of
the ligand suggests that it is not interaction with CRABPII
that prevents genomic signalling in the case of DC479, which is
discussed further below.
3.4. Crystal structure of CRABPII–DC645
DC645 was developed as part of a library of synthetic
retinoids following the EC23 archetype but lacking the fluor-
escence-enhancing elements used in earlier series (including
DC479). Instead, a tetrahydroquinoxaline derivative offers
enhanced hydrogen-bonding opportunities in the mid-section,
creating interactions with solvent and Arg60 at the mouth of
the binding site, which is likely to help to stabilize the protein–
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Figure 2
(a) CRABPI-L29C with the binding triad (Arg112-Arg132-Tyr134) (ribbon representation, pale blue; O atoms, red; N atoms, blue) and a conserved
water molecule hydrogen-bonded to the associated DC645 ligand (brick red; O atoms, red; N atoms, blue). The asymmetric unit is composed of two
independent monomers; one ligand-bound (chain A, shown) and one with an unoccupied binding site (the r.m.s.d. between chains A and B on C atoms is
0.64 Å). (b) Ligand density of DC645 in chain A in the ligand-binding site of CRABPI-L29C (2Fo  Fc map including ligand, contour  = 1.00). (c)
Chemical structure of DC645.
ligand complex. DC645 was chosen for co-crystallization
owing to the increasing evidence of its positive effect on
neurite outgrowth in cellular models of Alzheimer’s disease
(Khatib et al., 2020).
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Figure 4
DC645 (brick red; O atoms, red; N atoms, blue) incorporated into the binding site of CRABPII (ribbon representation, dark blue; O atoms, red; N atoms,
blue). The key binding resides Arg112-Arg133-Tyr135 and a conserved water molecule (dark blue; O atoms, red; N atoms, blue) can be seen at the base
of the hydrophobic pocket with predicted hydrogen bonding. NLS-forming residues (white; N atoms, blue) can be seen facing externally on the left. (b)
Ligand density of DC645 in chain A in the ligand-binding site of CRABPII (2Fo  Fc map including ligand, contour  = 2.00).
Figure 3
(a) DC479 (depicted in stick representation, pink) incorporated into the binding site of CRABPII (ribbon representation, dark blue; O atoms, red; N
atoms, blue). The key binding resides (Arg112-Arg133-Tyr135) and a conserved water molecule can be seen at the base of the hydrophobic pocket with
predicted hydrogen bonds to the ligand (dark blue; O atoms, red; N atoms, blue). NLS-forming residues (white; N atoms, blue) can be seen facing
externally on the left. The protein forms a dimer with noncrystallographic symmetry, of which chain A is displayed for clarity. The r.m.s.d. between chains
A and B on C atoms is 0.23 Å. (b) Ligand density of DC479 in chain A in the ligand-binding site of CRABPI (2Fo Fc map including ligand, contour  =
1.50). (c) Chemical structure of DC479.
The structure shown in Fig. 4, at a resolution of 1.71 Å,
consists of a single CRABPII monomer with a near-identical
structure to previous depositions (PDB entry 5ogb; r.m.s.d. of
0.73 Å on C atoms). The incorporation of DC645 into the
CRABPII binding site, fully engaged with the binding triad, is
an important step in understanding its interaction with the
retinoid signalling pathway and indicates that the molecule
will be transported to the nucleus.
3.5. Competitive binding assays
To fully characterize the interaction between the protein
and the ligand, the binding of DC645 to CRABPII and
CRABPI-L29C was assessed using a previously published
assay technique (Tomlinson et al., 2018). By interpreting the
displacement of a solvatochromic, fluorescent (and therefore
easily quantified) retinoid from the binding site of CRABPII,
the relative binding affinity of a second molecule, which would
otherwise be hard to detect, can be determined. Minor
modifications were made to the controls to allow for the fact
that DC645 displays some small intrinsic fluorescence at the
typical emission wavelength of 440 nm, which is likely to be
the tail of a larger fluorescence in the sub-400 nm region. It
was also demonstrated that DC645 was not solvatochromic
with respect to CRABPII (Fig. 5a), i.e. the absolute fluores-
cence of the molecule in solution was not dependent on the
CRABPII concentration and therefore was not dependent on
incorporation into the binding site. This allowed the assay to
be undertaken as normal, with background controls
accounting for the low-level DC645 fluorescence. Using
DynaFit to fit the data (Fig. 5b), a Kd value of 0.25  0.06 mM
was determined for the binding of DC645 to CRABPII
(Kuzmič, 1996).
Similar competitive analysis (Fig. 8) showed that CRABPI-
L29C interacts less favourably with DC645, with a Kd value of
1.94  0.11 mM being determined for this pair. This may
explain why only one of the two ligand-binding sites in the
crystal structure is ligand-occupied, with the interaction being
considerably weaker than in other retinoid/binding-protein
pairs. For comparison of ligand-binding poses, least-squares
superposition on C atoms was carried out using CCP4mg
(McNicholas et al., 2011), giving an r.m.s.d. between the two
structures of 0.81 Å (Fig. 6b). The ligand-binding residues and
the carboxylic acid motif of the ligand are very closely aligned,
with a slight deviation of the tetrahydroquinoxaline tail groups
between the CRABPI-L29C and CRABPII structures. The
slight relative translation of the molecule between the two
structures is owing to the internal geometry of the binding site,
which, although closely structurally conserved, does contain
some modifications.
4. Discussion
CRABPI and CRABPII adopt closely related tertiary struc-
tures consisting of a pair of orthogonal five-stranded -sheets
capped by two -helices. This structure creates a hydrophobic
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Figure 5
(a) Analysis of retinoid fluorescence of DC271 and DC645 in the presence and absence of CRABPII (n = 3). It can be seen that DC271 presents a stark
solvatochromic effect when in the presence of CRABPII owing to inclusion into the binding site, as discussed previously (Chisholm et al., 2019). DC645
conversely displays some intrinsic fluorescence but no solvatochromic effect. (a) Binding analysis of DC645 to CRABPII by the displacement of DC271;
curve fitting was performed using DynaFit (Kuzmič, 1996; Tomlinson et al., 2018).
binding pocket suitably sized for ATRA, with a triad of
binding residues at its core and a swathe of hydrophobic side
chains lining the pocket. This canonical structure can be
considered to be the active and normal form of the protein and
is adopted in all of the ligand-bound structures thus far
obtained in this project.
4.1. Effect of the binding of DC645 on the CRABPII NLS and
comparison to ATRA
DC645 is amongst a number of retinoid-based drug candi-
dates that have been proposed for a suite of neurodegenera-
tive diseases, including ALS and Alzheimer’s disease. These
RAR-modulating (RAR-M) compounds have been shown to
diversely induce neurotrophic genes, suppress lipopoly-
saccharide-induced inflammation systems and promote the
non-amyloidogenic pathway, suggesting the option to tailor
activities for maximum effect in different pathologies (Khatib
et al., 2020).
The limited flexibility of CRABPII and the lack of signifi-
cant structural changes when a ligand is introduced focuses the
characterization of protein–ligand interactions onto whether
or not a ligand is incorporated into the binding site. Super-
position of CRABPII–DC645 with an ATRA-containing
structure (PDB entry 1cbs) also allows comparison between
the binding position of ATRA and that of the synthetic reti-
noid. As shown in Fig. 7(c), the binding pose is near-identical
and key carboxylic acid residues align closely with those of the
natural ligand. Suitable conditions for hydrogen bonding can
also be seen between the highly aligned binding triad Arg112-
Arg133-Tyr135, the ligand and the typically conserved water
molecule which serves to bridge hydrogen bonding to Arg112.
Successful ligand incorporation creates a small but notable
outward inversion of Arg29, which alongside Lys20/Lys30
creates a basic region in the electrostatic surface of the protein
and forms the ‘noncanonical’ nuclear localization sequence
(Fig. 7). Such a shift in position suggests that a ligand will be
transported through the nuclear pore and into the nucleus,
allowing the opportunity to influence the signalling of both
RAR and RXR proteins through the canonical pathway. This
can be seen in the case of CRABPII–DC645 (Fig. 7), in which
Arg29 is surface-exposed and aligned closely with the same
residue as in ATRA-occupied CRABPII (PDB entry 1cbs),
creating the desirable basic surface region. This residue is
similarly exposed in the structure of CRABPII–DC479,
suggesting that the lack of genomic signalling previously seen
is not owing to a failed interaction with the carrier protein, but
is rather the result of a downstream clash with the RAR/RXR
signalling system. Whilst both ligands fulfil the necessary
criteria for nuclear import, it is clear that corresponding in
vivo studies are vital to fully understand the activity of RAR/
RXR in the nucleus.
4.2. CRABPI–L29C ligand interaction and nongenomic mode
of action
To date, CRABPI had only been crystallized using the
proteins from M. musculus and B. taurus. Whilst they are
nearly identical, H. sapiens CRABPI contains a single amino-
acid shift from alanine to proline at position 86. This single
variation can be found in the lower -sheet region proposed to
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Figure 6
(a) Competitive displacement of DC271 from CRABPI-L29C by DC645 was carried out using a previously discussed methodology; curve fitting was
carried out by least-squares regression using DynaFit (n = 6,  = 0.05; Tomlinson et al., 2018; Kuzmič, 1996). (b) Superposition of CRABPII-DC645
(ribbon representation, dark blue; O atoms, red; N atoms, blue) and CRABPI-L29C–DC645 (ribbon representation, pale blue; O atoms, red; N atoms,
blue) cut away to show the similarity of the ligand pose (cylinder representation; CRABPII–DC645, brick red; CRABPI-L29C–DC645, brown). The
CRABPII nuclear localization sequence is shown (cylinder representation, white; N atoms, blue). The r.m.s.d. on C atoms is 0.81 Å.
be the site of interaction for Raf kinases related to non-
genomic activity pathways (Park et al., 2019). It is evident from
alignment with PDB entry 1cbr (Fig. 8a) that this mutation has
no great effect upon either the location or the orientation of
any local residues and has no overall impact on the general
structure (Kleywegt et al., 1994). This suggests that work
modelled on CRABPI from M. musculus is relevant to the
activity of the human protein.
The incorporation of a ligand into the binding site of
CRABPI is currently the best available structural indicator of
ligand efficacy. NMR-based studies have suggested that
interactions between CRABPI and the Raf kinase involved in
nongenomic pathway signalling are made at the base of the
-sandwich: the opposite end to the ligand-binding pocket
(Park et al., 2019). Whilst no specific sites or residues are
indicated, the data suggest a method of allosteric interaction
that has not yet been fully characterized. It can be seen in the
structure of CRABPI-L29C–DC645 (Fig. 8b) that there are
several residues that adopt alternate side-chain conformations
after ligand binding (aligning the ligand-occupied A chain with
the unoccupied B chain) but that no overall structural rear-
rangement is noted beyond a slight constriction of the binding
pocket. It should be noted that these residues fall within the
region through which dimerization occurs, which may either
contribute to their alternate conformations or be a direct
result of it, allowing unoccupied/ligand-occupied cross-
dimerization to occur. It is also of interest that Arg45, Asp47,
Gln50 and Arg83 are amongst the few residues found in
CRABPI that differ relative to CRABPII. Without further
study of the specific interactions governing nongenomic
signalling of CRABPI, it is difficult to assign a role to any
specific residue or area of the protein, but nevertheless the
high-resolution structural determination of CRABPI in the
presence and absence of ligands will assist in the future
development of this understanding.
The structures presented above may also offer some insight
into why CRABPII binds DC645 with greater efficacy than
CRABPI-L29C. It can be seen in the ligand-binding site that
residue Arg60, which is positioned to
create a hydrogen-bonding network
between the ligand and several water
molecules in CRABPII, does not have
the same orientation relative to the
ligand in CRABPI-L29C. It could be
this small interaction that makes the
binding far more favourable in the
nuclear transport protein in comparison
to its cytoplasm-bound cousin.
These high-resolution structures of
CRABPI provide insight into how the
protein compares favourably to murine
and bovine orthologues, as well as how
ligand binding affects the protein. It can
be seen that DC645 binds to CRABPI
in the canonical manner, with a deeply
buried head group interacting with
three members of a binding triad, and
that its incorporation into the protein
creates subtle shifts in residues and
regions that may contribute to the
previously discussed nongenomic inter-
action pathway.
5. Summary and conclusions
The confirmation that no major struc-
tural rearrangement occurs when
CRABPI binds to a ligand adds
credence to the idea that the inter-
actions of CRABPI with relevant
binding partners to modulate non-
genomic activity are mediated through
subtle surface effects, including those
described previously. It is notable that
several residues in the lower -sandwich
region adopt alternate side-chain
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Figure 7
Comparison of (a) unoccupied CRABPII (PDB entry 1xca, grey) and (b) the DC645 ligand-
occupied complex (blue) aligned with the ATRA ligand-occupied structure (PDB entry 1cbs,
white). Arrows denote the direction of movement as residues adopt the ligand-occupied
conformation. (c) Cut-away alignment of CRABPII–DC645 (dark blue) and PDB entry 1cbs
(white), showing the similarity between the orientation of DC645 (brick red; O atoms, red; N atoms,
blue) and ATRA (green; O atoms, red; N atoms, blue) and their interaction with the binding triad
Arg112-Arg133-Tyr135 and a conserved water molecule. The r.m.s.d. on C atoms is 0.48 Å.
conformations between the vacant and ligand-bound forms of
the protein and could be implicated in this process based on
literature data. In the case of CRABPII, it has been demon-
strated that several non-ATRA retinoid derivatives can
generate suitable NLS interaction sites to prompt their import
into the nucleus. This confirms a role for CRABPII in the
transport of newly developed drug molecules to the relevant
nuclear receptors, which is a key step in creating a selective
retinoid drug and potentially a novel treatment regime for the
many pathologies that retinoid signalling pathways influence.
When considering the design of ligands for drug-devel-
opment programs, it is important to bear in mind that any
ligand that is designed to interact with CRABPII, and hence
be transported to the nucleus, may also have impacts upon
the nongenomic signalling of CRABPI and as a direct result
introduce unexpected phenotypic changes. It has been
previously demonstrated that nongenomic and genomic
pathways work in harmony as part of retinoid signalling,
particularly in the case of neurite outgrowth in cell cultures,
where compounds capable of inducing both pathways were
most successful (Khatib et al., 2019). Owing to the high
sequence and structural similarity between the CRAB
proteins, aiming to specifically trigger CRABPI and the
nongenomic signalling pathway may prove difficult without
the ability to design exceptionally selective ligands. The design
of such ligands will rely heavily on data from high-throughput
assays and, as demonstrated above in the semi-selectivity of
DC645 for CRABPII over CRABPI, the linking of structural
understanding with such data as new candidate molecules are
selected. Through better understanding of both pathways, and
the relative interactions of ligands with their cognate proteins,
it may be possible to develop the selectivity needed to
meaningfully modify retinoid signalling in vivo at a level
that distinguishes between the genomic and nongenomic
pathways.
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